Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Sarah Jessica Parker divides opinion with enormous hat on set of And Just Like ThatFarm family’s newest crop shows China’s solar ascendancyGrant Shapps vows he WILL find more planes for mass parachute drop to mark 80th anniversary of DThe 13 style rules that every midlife woman MUST follow (and yes, beige really is banned!)Israeli army says it kills over 130 militants in E. RafahAbbey Clancy, 38, shows off a new set of train track braces as she's left redForensic psychiatrist reveals the different types of stalkersGreek judge dismisses case against 9 Egyptians accused of causing a deadly shipwreckWildfires sweep across Finland, straining rescue servicesHow Diddy made himself the 'victim' in apology video where he does not mention ex
2.9596s , 6497.9140625 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Culture Compass news portal